.Market research, communication and marketing strategy
Forestry products.
Tiller.Distributor
Hospital gowns, Gloves, Bandages&tapes Bowel&gastric, Packs&trays, Dialysis, Garments Hypodermic supplies, Infection control Orthopedics Mask Surgical instruments Urologie &ostomy Waste management Wound care And more.....
.All tasks involved in international trading (searches, customs, compliance, registration for business in Canada, etc.) - qualified itt and qualified custom broker (for Canada) - mention of honour for international management at fitt exam.
Plastic scrap, paper scrap and metal scrap, car engines scrap.Recycling managment
Made in Canada Health Canada approved CE Mark and ISO certified The product has proven to have 100% Specificity and 96% Sensitivety Stock availabity: 2 Million tests/kit in Canada Production: up to 5 Million tests/kit weekly The Rapid Response COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset. This test is authorized for use at the Point of Care i.e., in patient care setting. Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigen is generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patientâ??s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The Rapid Responseâ?¢ COVID-19 Antigen Rapid Test Device is for use at the Point of Care for professional use only. PRODUCT INFORMATION: Product: Rapid Respose Sample: Nasal / Nasopharyngeal secretions Format: Cassette Quantity: 25 Tests/Kit per box Time to result: 15 minutes Storage Condition: 2-30 C/36-86 F Test Principle: Immunochromatographic Assay CONTENTS - Individually packed test devices Extraction Buffer Extraction tube Nozzle with filter Tube stand Individually packed swabs Package Insert
